Zydus Cadila has received final approval from the United States Food & Drug Administration (USFDA) to market Memantine Hydrochloride tablets USP, 5mg and 10mg. The drug is use for the treatment of moderate to severe dementia of the Alzheimer’s type and will be produced at the group’s formulations manufacturing facility at Moraiya in Ahmedabad.
The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
